Clinical trial · no report yet · Phase 3
SENTRY
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- NCT04562389 ↗
- Active not recruiting
- Karyopharm Therapeutics Inc
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Myelofibrosis
- Interventions
- Selinexor; Selinexor; Placebo; Ruxolitinib
- Arms
- Phase 1a: Cohort 1: Selinexor 40 mg + Ruxolitinib BID · Experimental
- Phase 1a: Cohort 2: Selinexor 60 mg + Ruxolitinib BID · Experimental
- Phase 1b: Selinexor and Ruxolitinib BID · Experimental
- Phase 3: Selinexor 60 mg + Ruxolitinib BID · Experimental
- Phase 3: Placebo + Ruxolitinib BID · Active comparator
- Enrollment
- 353
- Primary outcomes
- Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan
- Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0
- Phase 1: Maximum Tolerated Dose (MTD)
- Phase 1: Recommended Phase 2 Dose (RP2D)
- Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity
- Sponsor
- Karyopharm Therapeutics Inc
- Start
- Mar 11, 2021
- Primary completion
- Feb 20, 2026
- Results posted
- No
- Registry record
- NCT04562389 · updated Oct 1, 2026
Publications
linked from the registry- Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J; SENTRY Trial Investigators. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naive Myelofibrosis: Phase III SENTRY Trial. J Clin Oncol. 2026 Aug;44(22):2098-2109. doi: 10.1200/JCO-26-01080. Epub 2026 Jun 2. PubMed 42227656
- Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, Gudi G, Taverna P, Mark T, Tantravahi SK. Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study. Blood Adv. 2026 May 26;10(10):3383-3397. doi: 10.1182/bloodadvances.2025018706. PubMed 41785311
- Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C; SENTRY investigators. Selinexor plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis: SENTRY Phase 3 study design. Future Oncol. 2025 Mar;21(7):807-813. doi: 10.1080/14796694.2025.2461393. Epub 2025 Feb 6. PubMed 39911057